Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR Morbidity and Mortality Weekly Report,
Год журнала:
2024,
Номер
73(16), С. 377 - 381
Опубликована: Апрель 25, 2024
COVID-19
remains
an
important
public
health
threat,
despite
overall
decreases
in
COVID-19-related
severe
disease
since
the
start
of
pandemic.
COVID-19-associated
hospitalization
rates
remain
higher
among
adults
aged
≥65
years
relative
to
younger
adults,
adolescents,
and
children;
during
October
2023-January
2024,
67%
all
hospitalizations
were
persons
years.
On
September
12,
2023,
CDC's
Advisory
Committee
on
Immunization
Practices
(ACIP)
recommended
updated
(2023-2024
Formula)
vaccination
with
a
monovalent
XBB.1.5-derived
vaccine
for
≥6
months
protect
against
illness
death.
Because
SARS-CoV-2
continues
circulate
throughout
year,
because
increased
risk
years,
protection
afforded
by
vaccines
JN.1
other
currently
circulating
variants,
expected
waning
vaccine-conferred
disease,
February
28,
ACIP
receive
1
additional
dose
vaccine.
Implementation
these
recommendations
is
enhance
immunity
that
might
have
waned
decrease
outcomes,
including
death,
Язык: Английский
Overview of U.S. COVID-19 vaccine safety surveillance systems
Vaccine,
Год журнала:
2024,
Номер
42, С. 125748 - 125748
Опубликована: Апрель 16, 2024
The
U.S.
COVID-19
vaccination
program,
which
commenced
in
December
2020,
has
been
instrumental
preventing
morbidity
and
mortality
from
disease.
Safety
monitoring
an
essential
component
of
the
program.
federal
government
undertook
a
comprehensive
coordinated
approach
to
implement
complementary
safety
systems
communicate
findings
timely
transparent
way
healthcare
providers,
policymakers,
public.
Monitoring
involved
both
well-established
newly
developed
that
relied
on
spontaneous
(passive)
active
surveillance
methods.
Clinical
consultation
for
individual
cases
adverse
events
following
was
performed,
special
populations,
such
as
pregnant
persons,
conducted.
This
report
describes
government's
vaccine
programs
used
by
Centers
Disease
Control
Prevention,
Food
Drug
Administration,
Department
Defense,
Veterans
Affairs,
Indian
Health
Service.
Using
event
myocarditis
mRNA
model,
we
demonstrate
how
multiple,
worked
rapidly
detect,
assess,
verify
signal.
In
addition,
longer-term
follow-up
conducted
evaluate
recovery
status
vaccination.
Finally,
process
communication
dissemination
data
is
described,
highlighting
responsiveness
robustness
infrastructure
during
national
Язык: Английский
Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR Morbidity and Mortality Weekly Report,
Год журнала:
2024,
Номер
73(49), С. 1118 - 1123
Опубликована: Дек. 12, 2024
This
report
describes
CDC's
recommendation
that
all
people
aged
≥65
years
and
ages
6
months–64
with
moderate
or
severe
immunocompromise
receive
a
second
2024–2025
COVID-19
vaccine
dose
months
after
their
last
dose.
Язык: Английский
Development of COVID-19 vaccine policy — United States, 2020–2023
Vaccine,
Год журнала:
2023,
Номер
unknown, С. 125512 - 125512
Опубликована: Дек. 1, 2023
COVID-19
vaccines
represent
a
great
scientific
and
public
health
achievement
in
the
face
of
overwhelming
pressures
from
global
pandemic,
preventing
millions
hospitalizations
deaths
due
to
United
States.
Over
675
million
doses
have
been
administered
States,
over
80%
U.S.
population
has
had
at
least
1
dose
vaccine.
course
pandemic
one
people
died
COVID-19,
six
were
hospitalized.
It
estimated
that
prevented
more
than
18
additional
3
From
beginning
2020
through
June
2023,
ACIP
35
focused
meetings
24
votes
for
vaccine
recommendations.
critical
task
rapidly
thoroughly
reviewing
emerging
evolving
data
on
epidemiology
vaccines,
as
well
making
comprehensive
population-based
recommendations
policy
considerations
implementation
transparent
evidence-based
framework.
Safe
effective
recommended
discussions
with
ACIP,
remain
best
tool
we
prevent
serious
illness,
hospitalization
death
COVID-19.
Язык: Английский
Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic
Vaccine,
Год журнала:
2024,
Номер
42, С. 125644 - 125644
Опубликована: Фев. 29, 2024
Язык: Английский
Reflections on The Advisory Committee on Immunization Practices during the COVID-19 Pandemic
Academic Pediatrics,
Год журнала:
2024,
Номер
24(7), С. 1038 - 1046
Опубликована: Сен. 1, 2024
Язык: Английский
Postmarketing Vaccine Safety Assessments
JAMA,
Год журнала:
2024,
Номер
331(11), С. 915 - 915
Опубликована: Март 19, 2024
Our
website
uses
cookies
to
enhance
your
experience.
By
continuing
use
our
site,
or
clicking
"Continue,"
you
are
agreeing
Cookie
Policy
|
Continue
JAMA
HomeNew
OnlineCurrent
IssueFor
Authors
Journals
Network
Open
Cardiology
Dermatology
Health
Forum
Internal
Medicine
Neurology
Oncology
Ophthalmology
Otolaryngology–Head
&
Neck
Surgery
Pediatrics
Psychiatry
Archives
of
(1919-1959)
Podcasts
Clinical
Reviews
Editors'
Summary
Medical
News
Author
Interviews
More
JN
Learning
/
CMESubscribeJobsInstitutions
LibrariansReprints
Permissions
Terms
Use
Privacy
Accessibility
Statement
2024
American
Association.
All
Rights
Reserved
Search
Archive
Input
Term
Sign
In
Individual
inCreate
an
Account
Access
through
institution
Purchase
Options:
Buy
this
article
Rent
Subscribe
the
journal
Язык: Английский